#thelancet — Public Fediverse posts

DATE: September 8, 2026 at 11:00AM
SOURCE: PSYPOST.ORG

** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------

TITLE: Antidepressants show wide variation in physical side effects

URL: https://www.psypost.org/antidepressants-show-wide-variation-in-physical-side-effects/

Different antidepressants can have drastically different effects on a patient’s physical health, according to a recent review of medical research. Some medications cause substantial weight gain and increased blood pressure, while others lead to weight loss and lowered heart rates. The findings were published in The Lancet.

Millions of people rely on prescription medications to manage mental health conditions. Up to 17 percent of adults in Europe and North America currently take antidepressants. While these drugs are effective at treating mood disorders, they can also cause unintended bodily changes. These physical side effects are a common reason why people stop taking their prescribed treatments.

Medical guidelines recommend that doctors discuss potential physical changes with patients before starting a prescription. However, it can be difficult for physicians to provide precise comparisons between specific drugs.

Toby Pillinger and Atheeshaan Arumuham of King’s College London led the research team to address this knowledge gap. They worked alongside other international experts, including Orestis Efthimiou of the University of Bern, Oliver D. Howes of King’s College London, and Andrea Cipriani of the University of Oxford. The team wanted to determine exactly how different medications compare in terms of physical side effects. They also wanted to see if factors like age or starting weight influenced these bodily reactions.

To answer these questions, the researchers conducted a network meta-analysis. This type of statistical study pools data from multiple independent trials. It allows researchers to compare treatments that might never have been tested directly against each other in the same room. By linking trials through a common comparator, researchers can estimate how two different drugs would perform head-to-head.

The team gathered data from 151 randomized controlled trials and 17 government regulatory reports. The resulting large study included 58,534 participants. The researchers evaluated 30 different antidepressants prescribed for acute psychiatric treatment, which typically lasted about eight weeks.

The analysis revealed major differences in how these drugs affect body weight. People taking agomelatine experienced the most weight loss, losing an average of about 2.4 kilograms compared to those taking a placebo, an inactive control pill. On the other end of the spectrum, maprotiline and amitriptyline caused the most weight gain, adding up to 1.8 kilograms on average. This created a roughly four-kilogram gap between the highest and lowest weight-altering medications.

The researchers estimated that almost half of the people taking maprotiline or amitriptyline would gain a noticeable amount of weight. Medications that caused the most weight gain were generally those known to block specific histamine and serotonin receptors, which act as chemical docking stations in the brain. Over time, extra weight can elevate a person’s risk for metabolic issues and joint stress.

Cardiovascular changes also varied widely depending on the specific medication. Nortriptyline increased patients’ heart rates by an average of nearly 14 beats per minute. By contrast, fluvoxamine lowered heart rates by about eight beats per minute. This difference amounts to a 21-beat-per-minute gap between the two drugs.

Blood pressure effects showed a similar split among the evaluated medications. Amitriptyline raised systolic blood pressure, which measures the pressure in your arteries when your heart beats, by almost five millimeters of mercury. Nortriptyline lowered the same metric by over six millimeters of mercury. The researchers noted that these cardiovascular shifts could influence a patient’s long-term risk for heart disease, especially if the changes persist over several years.

The medications that increased blood pressure were largely serotonin-noradrenaline reuptake inhibitors, or tricyclic antidepressants. These drug classes share a mechanism that affects the neurotransmitter noradrenaline. This chemical messenger plays a well-documented role in blood pressure regulation.

The researchers also tracked metabolic markers like cholesterol and blood sugar. Paroxetine, duloxetine, desvenlafaxine, and venlafaxine were associated with measurable increases in total cholesterol. Duloxetine was also linked to increased blood glucose levels. These metabolic increases occurred even though the medications themselves generally caused patients to lose body weight.

Some medications also affected liver function tests. Duloxetine, desvenlafaxine, and levomilnacipran caused increases in the concentration of certain liver enzymes. These enzymes are proteins that help the organ filter blood and break down medications. While these enzyme elevations were substantial enough to measure, the researchers noted that the amounts were not high enough to pose an immediate medical threat to most patients.

The team did not find that any of the evaluated antidepressants altered heart rhythm intervals to a problematic degree. The medications also did not have a strong effect on sodium levels, potassium levels, or kidney function markers during the trial periods.

In a separate analysis, the researchers examined how patient characteristics influenced these side effects. They used a statistical technique called meta-regression to look for trends across the different study populations. They found that groups of patients with higher starting body weights experienced larger medication-induced increases in blood pressure and liver enzymes. Populations with a higher average age saw larger medication-induced increases in blood sugar.

Finally, the team wanted to know if experiencing physical side effects was linked to mental health improvements. In patients with severe psychiatric conditions like schizophrenia, past research has shown a correlation between metabolic disturbances and improved symptoms. To test this concept in depression, the researchers looked specifically at trials involving patients with major depressive disorder.

The researchers compared the change in depressive symptoms against changes in weight, cholesterol, and blood sugar across the studies. They did not find a correlation between improved mental health and metabolic side effects. This suggests that patients do not need to experience physical changes to get the mental health benefits of the medication.

A primary limitation of this research is the short duration of the included trials. Most studies lasted only eight weeks, meaning the long-term physical effects of these medications remain unconfirmed by this specific analysis. Some cardiovascular shifts might fade over time, while other metabolic changes could worsen over a period of years.

The trials also mostly included younger, relatively healthy individuals taking only one medication. This focus might obscure side effects that occur more frequently in older adults or people taking multiple drugs at once. Real-world observational data suggests that certain antidepressants might increase the risk of low sodium or heart rhythm problems in older populations. The researchers suggest that doctors should consider both clinical trial data and real-world observations when prescribing medications to older or medically vulnerable patients.

The study, “The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis,” was authored by Toby Pillinger, Atheeshaan Arumuham, Robert A McCutcheon, Enrico D’Ambrosio, Georgios Basdanis, Marco Branco, Richard Carr, Valeria Finelli, Toshi A Furukawa, Siobhan Gee, Adrian Heald, Sameer Jauhar, Zihan Ma, Valentina Mancini, Calum Moulton, Georgia Salanti, David M Taylor, Anneka Tomlinson, Allan H Young, Orestis Efthimiou, Oliver D Howes, and Andrea Cipriani.

URL: https://www.psypost.org/antidepressants-show-wide-variation-in-physical-side-effects/

-------------------------------------------------

Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org

Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

-------------------------------------------------

#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #Antidepressants #SideEffects #Cardiometabolic #DepressionTreatment #WeightChange #BloodPressure #Cholesterol #MetabolicHealth #NetworkMetaAnalysis #TheLancet

DATE: September 8, 2026 at 11:00AM
SOURCE: PSYPOST.ORG

** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------

TITLE: Antidepressants show wide variation in physical side effects

URL: https://www.psypost.org/antidepressants-show-wide-variation-in-physical-side-effects/

Different antidepressants can have drastically different effects on a patient’s physical health, according to a recent review of medical research. Some medications cause substantial weight gain and increased blood pressure, while others lead to weight loss and lowered heart rates. The findings were published in The Lancet.

Millions of people rely on prescription medications to manage mental health conditions. Up to 17 percent of adults in Europe and North America currently take antidepressants. While these drugs are effective at treating mood disorders, they can also cause unintended bodily changes. These physical side effects are a common reason why people stop taking their prescribed treatments.

Medical guidelines recommend that doctors discuss potential physical changes with patients before starting a prescription. However, it can be difficult for physicians to provide precise comparisons between specific drugs.

Toby Pillinger and Atheeshaan Arumuham of King’s College London led the research team to address this knowledge gap. They worked alongside other international experts, including Orestis Efthimiou of the University of Bern, Oliver D. Howes of King’s College London, and Andrea Cipriani of the University of Oxford. The team wanted to determine exactly how different medications compare in terms of physical side effects. They also wanted to see if factors like age or starting weight influenced these bodily reactions.

To answer these questions, the researchers conducted a network meta-analysis. This type of statistical study pools data from multiple independent trials. It allows researchers to compare treatments that might never have been tested directly against each other in the same room. By linking trials through a common comparator, researchers can estimate how two different drugs would perform head-to-head.

The team gathered data from 151 randomized controlled trials and 17 government regulatory reports. The resulting large study included 58,534 participants. The researchers evaluated 30 different antidepressants prescribed for acute psychiatric treatment, which typically lasted about eight weeks.

The analysis revealed major differences in how these drugs affect body weight. People taking agomelatine experienced the most weight loss, losing an average of about 2.4 kilograms compared to those taking a placebo, an inactive control pill. On the other end of the spectrum, maprotiline and amitriptyline caused the most weight gain, adding up to 1.8 kilograms on average. This created a roughly four-kilogram gap between the highest and lowest weight-altering medications.

The researchers estimated that almost half of the people taking maprotiline or amitriptyline would gain a noticeable amount of weight. Medications that caused the most weight gain were generally those known to block specific histamine and serotonin receptors, which act as chemical docking stations in the brain. Over time, extra weight can elevate a person’s risk for metabolic issues and joint stress.

Cardiovascular changes also varied widely depending on the specific medication. Nortriptyline increased patients’ heart rates by an average of nearly 14 beats per minute. By contrast, fluvoxamine lowered heart rates by about eight beats per minute. This difference amounts to a 21-beat-per-minute gap between the two drugs.

Blood pressure effects showed a similar split among the evaluated medications. Amitriptyline raised systolic blood pressure, which measures the pressure in your arteries when your heart beats, by almost five millimeters of mercury. Nortriptyline lowered the same metric by over six millimeters of mercury. The researchers noted that these cardiovascular shifts could influence a patient’s long-term risk for heart disease, especially if the changes persist over several years.

The medications that increased blood pressure were largely serotonin-noradrenaline reuptake inhibitors, or tricyclic antidepressants. These drug classes share a mechanism that affects the neurotransmitter noradrenaline. This chemical messenger plays a well-documented role in blood pressure regulation.

The researchers also tracked metabolic markers like cholesterol and blood sugar. Paroxetine, duloxetine, desvenlafaxine, and venlafaxine were associated with measurable increases in total cholesterol. Duloxetine was also linked to increased blood glucose levels. These metabolic increases occurred even though the medications themselves generally caused patients to lose body weight.

Some medications also affected liver function tests. Duloxetine, desvenlafaxine, and levomilnacipran caused increases in the concentration of certain liver enzymes. These enzymes are proteins that help the organ filter blood and break down medications. While these enzyme elevations were substantial enough to measure, the researchers noted that the amounts were not high enough to pose an immediate medical threat to most patients.

The team did not find that any of the evaluated antidepressants altered heart rhythm intervals to a problematic degree. The medications also did not have a strong effect on sodium levels, potassium levels, or kidney function markers during the trial periods.

In a separate analysis, the researchers examined how patient characteristics influenced these side effects. They used a statistical technique called meta-regression to look for trends across the different study populations. They found that groups of patients with higher starting body weights experienced larger medication-induced increases in blood pressure and liver enzymes. Populations with a higher average age saw larger medication-induced increases in blood sugar.

Finally, the team wanted to know if experiencing physical side effects was linked to mental health improvements. In patients with severe psychiatric conditions like schizophrenia, past research has shown a correlation between metabolic disturbances and improved symptoms. To test this concept in depression, the researchers looked specifically at trials involving patients with major depressive disorder.

The researchers compared the change in depressive symptoms against changes in weight, cholesterol, and blood sugar across the studies. They did not find a correlation between improved mental health and metabolic side effects. This suggests that patients do not need to experience physical changes to get the mental health benefits of the medication.

A primary limitation of this research is the short duration of the included trials. Most studies lasted only eight weeks, meaning the long-term physical effects of these medications remain unconfirmed by this specific analysis. Some cardiovascular shifts might fade over time, while other metabolic changes could worsen over a period of years.

The trials also mostly included younger, relatively healthy individuals taking only one medication. This focus might obscure side effects that occur more frequently in older adults or people taking multiple drugs at once. Real-world observational data suggests that certain antidepressants might increase the risk of low sodium or heart rhythm problems in older populations. The researchers suggest that doctors should consider both clinical trial data and real-world observations when prescribing medications to older or medically vulnerable patients.

The study, “The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis,” was authored by Toby Pillinger, Atheeshaan Arumuham, Robert A McCutcheon, Enrico D’Ambrosio, Georgios Basdanis, Marco Branco, Richard Carr, Valeria Finelli, Toshi A Furukawa, Siobhan Gee, Adrian Heald, Sameer Jauhar, Zihan Ma, Valentina Mancini, Calum Moulton, Georgia Salanti, David M Taylor, Anneka Tomlinson, Allan H Young, Orestis Efthimiou, Oliver D Howes, and Andrea Cipriani.

URL: https://www.psypost.org/antidepressants-show-wide-variation-in-physical-side-effects/

-------------------------------------------------

Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org

Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

-------------------------------------------------

#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #Antidepressants #SideEffects #Cardiometabolic #DepressionTreatment #WeightChange #BloodPressure #Cholesterol #MetabolicHealth #NetworkMetaAnalysis #TheLancet

DATE: September 8, 2026 at 11:00AM
SOURCE: PSYPOST.ORG

** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------

TITLE: Antidepressants show wide variation in physical side effects

URL: https://www.psypost.org/antidepressants-show-wide-variation-in-physical-side-effects/

Different antidepressants can have drastically different effects on a patient’s physical health, according to a recent review of medical research. Some medications cause substantial weight gain and increased blood pressure, while others lead to weight loss and lowered heart rates. The findings were published in The Lancet.

Millions of people rely on prescription medications to manage mental health conditions. Up to 17 percent of adults in Europe and North America currently take antidepressants. While these drugs are effective at treating mood disorders, they can also cause unintended bodily changes. These physical side effects are a common reason why people stop taking their prescribed treatments.

Medical guidelines recommend that doctors discuss potential physical changes with patients before starting a prescription. However, it can be difficult for physicians to provide precise comparisons between specific drugs.

Toby Pillinger and Atheeshaan Arumuham of King’s College London led the research team to address this knowledge gap. They worked alongside other international experts, including Orestis Efthimiou of the University of Bern, Oliver D. Howes of King’s College London, and Andrea Cipriani of the University of Oxford. The team wanted to determine exactly how different medications compare in terms of physical side effects. They also wanted to see if factors like age or starting weight influenced these bodily reactions.

To answer these questions, the researchers conducted a network meta-analysis. This type of statistical study pools data from multiple independent trials. It allows researchers to compare treatments that might never have been tested directly against each other in the same room. By linking trials through a common comparator, researchers can estimate how two different drugs would perform head-to-head.

The team gathered data from 151 randomized controlled trials and 17 government regulatory reports. The resulting large study included 58,534 participants. The researchers evaluated 30 different antidepressants prescribed for acute psychiatric treatment, which typically lasted about eight weeks.

The analysis revealed major differences in how these drugs affect body weight. People taking agomelatine experienced the most weight loss, losing an average of about 2.4 kilograms compared to those taking a placebo, an inactive control pill. On the other end of the spectrum, maprotiline and amitriptyline caused the most weight gain, adding up to 1.8 kilograms on average. This created a roughly four-kilogram gap between the highest and lowest weight-altering medications.

The researchers estimated that almost half of the people taking maprotiline or amitriptyline would gain a noticeable amount of weight. Medications that caused the most weight gain were generally those known to block specific histamine and serotonin receptors, which act as chemical docking stations in the brain. Over time, extra weight can elevate a person’s risk for metabolic issues and joint stress.

Cardiovascular changes also varied widely depending on the specific medication. Nortriptyline increased patients’ heart rates by an average of nearly 14 beats per minute. By contrast, fluvoxamine lowered heart rates by about eight beats per minute. This difference amounts to a 21-beat-per-minute gap between the two drugs.

Blood pressure effects showed a similar split among the evaluated medications. Amitriptyline raised systolic blood pressure, which measures the pressure in your arteries when your heart beats, by almost five millimeters of mercury. Nortriptyline lowered the same metric by over six millimeters of mercury. The researchers noted that these cardiovascular shifts could influence a patient’s long-term risk for heart disease, especially if the changes persist over several years.

The medications that increased blood pressure were largely serotonin-noradrenaline reuptake inhibitors, or tricyclic antidepressants. These drug classes share a mechanism that affects the neurotransmitter noradrenaline. This chemical messenger plays a well-documented role in blood pressure regulation.

The researchers also tracked metabolic markers like cholesterol and blood sugar. Paroxetine, duloxetine, desvenlafaxine, and venlafaxine were associated with measurable increases in total cholesterol. Duloxetine was also linked to increased blood glucose levels. These metabolic increases occurred even though the medications themselves generally caused patients to lose body weight.

Some medications also affected liver function tests. Duloxetine, desvenlafaxine, and levomilnacipran caused increases in the concentration of certain liver enzymes. These enzymes are proteins that help the organ filter blood and break down medications. While these enzyme elevations were substantial enough to measure, the researchers noted that the amounts were not high enough to pose an immediate medical threat to most patients.

The team did not find that any of the evaluated antidepressants altered heart rhythm intervals to a problematic degree. The medications also did not have a strong effect on sodium levels, potassium levels, or kidney function markers during the trial periods.

In a separate analysis, the researchers examined how patient characteristics influenced these side effects. They used a statistical technique called meta-regression to look for trends across the different study populations. They found that groups of patients with higher starting body weights experienced larger medication-induced increases in blood pressure and liver enzymes. Populations with a higher average age saw larger medication-induced increases in blood sugar.

Finally, the team wanted to know if experiencing physical side effects was linked to mental health improvements. In patients with severe psychiatric conditions like schizophrenia, past research has shown a correlation between metabolic disturbances and improved symptoms. To test this concept in depression, the researchers looked specifically at trials involving patients with major depressive disorder.

The researchers compared the change in depressive symptoms against changes in weight, cholesterol, and blood sugar across the studies. They did not find a correlation between improved mental health and metabolic side effects. This suggests that patients do not need to experience physical changes to get the mental health benefits of the medication.

A primary limitation of this research is the short duration of the included trials. Most studies lasted only eight weeks, meaning the long-term physical effects of these medications remain unconfirmed by this specific analysis. Some cardiovascular shifts might fade over time, while other metabolic changes could worsen over a period of years.

The trials also mostly included younger, relatively healthy individuals taking only one medication. This focus might obscure side effects that occur more frequently in older adults or people taking multiple drugs at once. Real-world observational data suggests that certain antidepressants might increase the risk of low sodium or heart rhythm problems in older populations. The researchers suggest that doctors should consider both clinical trial data and real-world observations when prescribing medications to older or medically vulnerable patients.

The study, “The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis,” was authored by Toby Pillinger, Atheeshaan Arumuham, Robert A McCutcheon, Enrico D’Ambrosio, Georgios Basdanis, Marco Branco, Richard Carr, Valeria Finelli, Toshi A Furukawa, Siobhan Gee, Adrian Heald, Sameer Jauhar, Zihan Ma, Valentina Mancini, Calum Moulton, Georgia Salanti, David M Taylor, Anneka Tomlinson, Allan H Young, Orestis Efthimiou, Oliver D Howes, and Andrea Cipriani.

URL: https://www.psypost.org/antidepressants-show-wide-variation-in-physical-side-effects/

-------------------------------------------------

Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org

Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot

-------------------------------------------------

#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #Antidepressants #SideEffects #Cardiometabolic #DepressionTreatment #WeightChange #BloodPressure #Cholesterol #MetabolicHealth #NetworkMetaAnalysis #TheLancet

https://www.europesays.com/es/752348/ Un 40% de las personas con síndrome de Down y alzhéimer desarrollan epilepsia, lo que empeora la demencia #alzheimer #down #EmpeoraDemencia #Epilepsia #ES #España #Health #HospitalDeSantPau #MasRiesgo #personas #Salud #SantPau #síndrome #SíndromeDeDown #Spain #TheLancet

26 giu. 2026, dalla Redazione de ‘L’Antidiplomatico’: «”Complici del genocidio a Gaza”: la durissima petizione contro i medici israeliani pubblicata su The Lancet»

>> Oltre 1.150 professionisti e organizzazioni sanitarie hanno lanciato il 13 giugno una petizione per il boicottaggio dell’Associazione medica israeliana (IMA), accusandola di non rispettare l’etica medica e di dimostrare “complicità” nel genocidio dei palestinesi a Gaza.
L’iniziativa è guidata dal People’s Health Movement (PHM), da Medici per Gaza e dal Consiglio consultivo sanitario del gruppo Jewish Voice for Peace.
Le organizzazioni chiedono all’Associazione Medica Mondiale (WMA) di interrompere l’adesione all’IMA per il suo silenzio sulla sistematica distruzione delle infrastrutture sanitarie da parte di Israele e sull’uccisione, il rapimento e la tortura di medici, infermieri e soccorritori palestinesi.
La petizione è stata pubblicata anche su The Lancet, la rivista medica più prestigiosa al mondo. <<

[…]
l’articolo integrale è qui → https://www.lantidiplomatico.it/dettnews-complici_del_genocidio_a_gaza_la_durissima_petizione_contro_i_medici_israeliani_pubblicata_su_the_lancet/45289_67709/

🌡️🌡️ Dejar de trabajar por el #calorextremo es más frecuente en #Canarias que en cualquier otra región de Europa Un #estudio de #TheLancet estima que cada trabajador europeo con un empleo al aire libre pierde una media de 24 horas al año por las altas temperaturas. Canarias registró la mayor pérdida de todo el continente y expertas reclaman medidas de #adaptación

#Sociedad #ciencia #calentamientoglobal

✒️ Por Toni Ferrera

https://www.eldiario.es/canariasahora/ciencia_y_medio_ambiente/trabajar-calor-extremo-frecuente-canarias-region-europa_1_13370105.html

💪 ■ Los científicos coinciden: el histórico estudio que confirma que la salud mental ya incapacita más que el cáncer ■ Una profunda investigación publicada por la revista 'The Lancet' eleva a casi un 15% de la población mundial el total de afectados por algún tipo de enfermedad o episodio de […]
https://www.huffingtonpost.es/life/salud/los-cientificos-coinciden-historico-estudio-confirma-salud-mental-incapacita-mas-cancer-f202605.html?int=MASTODON_WORLD

#salud #saludmental #thelancet

The #clinicalTrial I've been participating in for a revolutionary new #cholera #vaccine has been published in #TheLancet, and the results are excellent.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00682-6/fulltext
I'm one of the data points in this article. 😉
The immunity from the new vaccine is so long-lasting that they're extending the study: they asked me to come back again in six months so they can test again to see if I still have immunity.
It's astonishing how many lives this vaccine will save.
#MedMastodon

El primer gran estudio científico realizado para evaluar las actitudes públicas hacia la teoría del #decrecimiento revela un apoyo significativo a sus ideas clave
Los resultados de este estudio, llevado a cabo por el #ICTA-UAB y la London School of Economics and Political Science (#LSE) y publicado en #TheLancet Planetary Health, ponen en entredicho la afirmación de que tales políticas no contarían con respaldo público

economiasolidaria.org
https://www.economiasolidaria.org/noticias/un-primer-estudio-integral-muestra-un-gran-apoyo-a-las-ideas-clave-del-decrecimiento-pero-no-al-termino/

#TheLancet Series on Ultra-Processed Foods & Human Health here:
https://www.thelancet....
#TheLancetTV
This 3-paper Series reviews the evidence about the increase in ultra-processed foods in diets globally & highlights the association with many non-communicable diseases. This rise in ultra-processed foods is driven by powerful global corporations who employ sophisticated political tactics to
protect & maximise profits. Education & relying on behaviour change by individuals is insufficient

A new three-paper series published in #TheLancet by 43 international experts warns that the global rise in ultra-processed foods #UPFs is a major #publichealth threat, driving an escalating burden of chronic diseases & reshaping diets worldwide
The series presents strong evidence linking UPF consumption to overeating, poor diet quality, increased risks of obesity, type 2 diabetes, cardiovascular disease, depression, early death, with 92 out of 104 reviewed studies reporting greater risks

I try to make it a rule in my life to never celebrate death.

But nor do I mourn unrepented #evil. Former US #VPOTUS Dick Cheney was deeply evil, a depraved #warCriminal and #torturer who should remain #despised.

The #IraqWar based on Cheney’s #BigLie turned millions of Iraqis into refugees. #TheLancet estimated 654,965 “excess deaths” in #Iraq during just the first 3 years of war.

#DickCheney embodied abuse of power, illegal war, torture, looting, and occupation. And he evaded #justice. 😡

Blasenkrebs im Frühstadium stoppen? Eine zusätzliche Immuntherapie macht den Unterschied. Im Vergleich zur Standardtherapie sank das Risiko für ein Voranschreiten oder Rückkehr des Tumors bei einer Kombinationstherapie um 32 Prozent, wie eine internationale klinische Studie unter Leitung der #CharitéBerlin zeigt. Jetzt in #TheLancet und beim Kongress der #ESMO.
👉 https://www.charite.de/forschung/themen_forschung/fortschritt_bei_blasenkrebs_im_fruehstadium
#Forschung #Wissenschaft #Medizin #Okologie #Immuntherapie

Au féminin
Cancer : une étude alarmante révèle pourquoi la France est le pays
https://mcinformactions.net/cancer-une-etude-alarmante-revele-pourquoi-la-france-est-le-pays-le-plus-touchele plus touché (environ 400 cas pour 100 000 habitants)
#Cancer #France #TheLancet

🇪🇺 Latest: European Public Health #BlueSky Starter Pack: 🆕 European Parliament Committee on #PublicHealth @sant.europarl.europa.eu 🆕 #TheLancet Regional Health - Europe @lancetrh-europe.bsky.social 🆕 MEPs for #WomensHealth @mepsforwomenhealth.bsky.social go.bsky.app/K2JB6CN

RE: https://bsky.brid.gy/convert/ap/at://did:plc:nnyqaearuxzfxq5kgtxcirl3/app.bsky.graph.starterpack/3l2mbgtswk32p

"The Lancet -tiedelehdessä julkaistun tutkimuksen mukaan USAIDin rahoitus oli vuosina 2001–2021 estänyt kehittyvissä valtioissa noin 91 miljoonaa kuolemaa.

The Lancetissa arvioidaan, että leikkaukset voivat vuoteen 2030 mennessä johtaa jopa 14 miljoonaan ylimääräiseen kuolemaan.

Vaikutus rinnastuu pandemian tai suuren aseellisen konfliktin aiheuttamaan tuhoon."

https://yle.fi/a/74-20179850

#Trump #Dump #äärioikeisto #USA #Yhdysvallat #kehitysapu #USAID #TheLancet

SHOCK: Israel Has Killed 20.7% of Gaza's Population. That's 434,000 People.

https://stevendonziger.substack.com/p/shock-israel-has-killed-207-of-gazas

"...First, the prestigious British medical journal #TheLancet conservatively estimated in a peer-reviewed analysis that as of 19 June 2024 roughly 186,000 Gazans had died from “direct” and “indirect” deaths since 8 October 2023.

That article and an explanation of the statistical model used is here.
To be clear, “direct” deaths under the model are caused by the Israeli military; “indirect” deaths are caused by a lack of access to food, water, and medical care (all largely denied by Israel to Gaza) and by disease...."

The larger issue is we need to think about what the scale of death means in terms of the human tragedy, and the extent of the legal impunity obtained thus far by #Netanyahu and his fascist government.

L’info était dans le JT d’Arte, et j’ai retrouvé l’article de l’Huma qui en parle :

« Selon une étude de la revue médicale The Lancet, publiée ce mardi 1er juillet, l’effondrement de Usaid pourrait engendrer la mort de plus de 14 millions de personnes dans les pays les plus vulnérables d’ici à 2030. Les enfants en dessous de cinq ans seraient les premières victimes. »

Salaud de Trump ! Salauds sa clique !

https://www.humanite.fr/monde/aide-humanitaire/les-coupes-budgetaires-americaines-dans-laide-humanitaire-internationale-pourraient-causer-la-mort-de-plus-de-14-millions-de-personnes-dici-a-2030-selon-une-etude-du-lancet

#USAID #TheLancet #Trump

USAID Formally Shut Down – Days After Scientists Warn Closure Will Kill 2.4 Million People Every Year https://healthpolicy-watch.news/usaid-shut-down-lancet-millions-deaths/ #SDGs #aid #health #TheLancet

🌐 ■ Los recortes de Trump en cooperación podrían causar 14 millones de muertes prevenibles en cinco años ■ Un estudio coordinado por el Instituto de Salud Global de Barcelona y publicado en 'The Lancet' pone números al cambio radical que supone el cierre de USAID.
https://www.huffingtonpost.es/global/los-recortes-trump-cooperacion-causar-14-millones-muertes-prevenibles-cinconosbr.html?int=MASTODON_WORLD

#donaldtrump #thelancet #global #eeuu #ayudahumanitaria #cooperacionydesarrollo

🩺 ■ De moverse en silla de ruedas a caminar: el tratamiento experimental que ha cambiado la vida de una joven con ELA ■ Un fármaco experimental podría beneficiar a algunos pacientes con un tipo raro y muy agresivo de la esclerosis lateral amiotrófica.
https://www.huffingtonpost.es/life/salud/de-silla-ruedas-volver-caminar-tratamiento-experimental-cambiado-vida-joven-elabr.html?int=MASTODON_WORLD

#esclerosismultiple #thelancet #salud #ciencia

A.
Here is another view of the likely death toll from the #Genocide in #Gaza.

It points at evidence that the official Ministry of Health figures are an undercount. And estimates the likely "deaths resulting from" in distinction to the "direct deaths".

Again from the #TheLancet.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01169-3/fulltext

"The Court's discussion is poorly informed and simplistic." — Prof Joe Herbert in #TheLancet on The UK Supreme Court's ruling on the definition of sex and the rights of #trans people.

Joe Herbert is Emeritus Professor of Neuroscience, Department of Clinical Neurosciences, University of Cambridge

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00834-7/fulltext

This week’s editorial of The Lancet (!):

> “Science and medicine in the USA are being violently dismembered while the world watches. While the risks to civil servants and academics’ livelihoods are real and understandably frightening, bullies are only emboldened by acquiescence or indifference.”

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00814-1/fulltext

#lancet #thelancet #uspol #science

If you want a #tattoo, apply #mehndi!

"#Tattoos as a risk factor for malignant #lymphoma: a population-based case–control study"

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00228-1/fulltext

#ChristelNielsen #MatsJerkeman #AnnaSaxneJöud #health #medicine #cancer #skin #TheLancet #henna #Sweden

"Instead of asking whether science should be political,
we should ask how politics can be more scientific." - Lancet Infectious Diseases editorial

https://doi.org/10.1016/S1473-3099(25)00089-1

#ScholarlyPublishing #TheLancet #PoliticizationOfScience #Censorship #AcademicFreedom #ScienceAdvice

"Instead of asking whether science should be political,
we should ask how politics can be more scientific." - Lancet Infectious Diseases editorial

https://doi.org/10.1016/S1473-3099(25)00089-1

#ScholarlyPublishing #TheLancet #PoliticizationOfScience #Censorship #AcademicFreedom #ScienceAdvice

"Instead of asking whether science should be political,
we should ask how politics can be more scientific." - Lancet Infectious Diseases editorial

https://doi.org/10.1016/S1473-3099(25)00089-1

#ScholarlyPublishing #TheLancet #PoliticizationOfScience #Censorship #AcademicFreedom #ScienceAdvice

"Instead of asking whether science should be political,
we should ask how politics can be more scientific." - Lancet Infectious Diseases editorial

https://doi.org/10.1016/S1473-3099(25)00089-1

#ScholarlyPublishing #TheLancet #PoliticizationOfScience #Censorship #AcademicFreedom #ScienceAdvice

"Instead of asking whether science should be political,
we should ask how politics can be more scientific." - Lancet Infectious Diseases editorial

https://doi.org/10.1016/S1473-3099(25)00089-1

#ScholarlyPublishing #TheLancet #PoliticizationOfScience #Censorship #AcademicFreedom #ScienceAdvice

Autistic groups worldwide pressure The Lancet on future research

https://au-ti.com/2022/02/14/autistic-groups-worldwide-pressure-the-lancet-on-future-research/

#AutisticSelfAdvocacyNetwork #ProfoundAutism #UnitedKingdom #DamianMilton #UnitedStates #HetaPukki #TheLancet #Advocacy #EUCAP #ASAN